Ind-Swift Laboratories Limited – Investor Presentation Summary

Key Operational Highlights

  • Operating income grew over 50% year-on-year in Q2 FY27
  • Scale-up of operations delivering operating leverage
  • Shift in business mix lifting margins with raw material cost decreasing as share of revenue
  • Global product registrations increased to 900+ from 750+ previously
  • Commercial validation of Clarithromycin Dry Suspension completed, expected commercialization shortly
  • CDMO partnerships/own brands commercialized, expected incremental revenue of ₹100-130 Cr in FY27
  • Development work on Warehouse at Derabassi unit commenced under Phase 1 of capex plan
  • Samba manufacturing facility upgrade to EU-GMP and PIC/S standards underway

Segment-wise Performance

  • Export Contract Manufacturing: 26.64% (Q1 FY27) and 26.99% (Q2 FY27) of total sales
  • Export Own-Brands: 56.72% (Q1 FY27) and 55.75% (Q2 FY27) of total sales
  • Domestic Ethical Division: 6.62% (Q1 FY27) and 5.43% (Q2 FY27) of total sales
  • Domestic Branded Generics: 6.84% (Q1 FY27) and 6.41% (Q2 FY27) of total sales
  • Domestic Contract Manufacturing (P2P): 3.61% of total sales

Financial Highlights

Q2 FY27 Standalone:

  • Revenue: ₹230.23 Cr
  • Operating EBITDA: ₹42.33 Cr
  • PAT: ₹31.03 Cr
  • Operating EBITDA Margin: 18.02%
  • PAT Margin: 13.21%
  • QoQ Revenue Growth: 25.18%
  • QoQ Operating EBITDA Growth: 27.04%
  • QoQ PAT Growth: 26.96%

H1 FY27 Standalone:

  • Revenue: ₹416.35 Cr
  • Operating Revenue: ₹420.97 Cr, up 35.79% YoY
  • Operating EBITDA: ₹75.65 Cr (4.5x YoY growth)
  • PAT: ₹55.47 Cr (3.3x YoY growth)
  • Operating EBITDA Margin: 17.97% (1249.34 BPS improvement YoY)
  • PAT Margin: 13.18% (773.35 BPS improvement YoY)

Drivers of financial performance: Higher revenue growth, operational efficiencies, business mix shift toward higher-margin segments

Geographical Revenue Split

  • Domestic vs Export mix not explicitly quantified in percentage terms
  • Presence across 85+ countries
  • Key export markets: Europe, UK, Australia, Canada, Africa, SEA, Middle East, Mexico
  • Domestic operations serve as "Stability Engine" providing consistent cash flow

Balance Sheet Snapshot

H1 FY27 Standalone:

  • Share Capital: ₹86.96 Cr
  • Reserves & Surplus: ₹1373.62 Cr
  • Total Equity: ₹1460.59 Cr
  • Long Term Borrowings: ₹15.14 Cr
  • Short-Term Borrowings: ₹4.34 Cr
  • Cash & Cash Equivalents: ₹322.81 Cr
  • Investments: ₹45.03 Cr
  • Net debt-free balance sheet status maintained

Financial Health Insights: Strong cash position, improved liquidity post-transformation

Capex & Cash Flow Health

  • Capital Expenditure: ₹250 Cr capex programme funded through internal accruals
  • CWIP: ₹41.82 Cr (H1 FY27)
  • Investment Rationale: Focus on capacity expansion, regulatory upgrades, warehouse development

Strategic & R&D Initiatives

  • Investments in Innovation: 70+ specialized scientists at Panchkula R&D centre
  • R&D focus on complex generics and differentiated formulations for regulated markets
  • 2,100+ dossiers filed across 85+ countries
  • 540+ product registrations owned by Ind-Swift
  • Active pipeline targeting cardiac, antidiabetic, urology, gastrointestinal, CNS therapies
  • Expected impact: 300+ new registrations in FY27 building long-term IP-led revenue visibility

Strategic Rationale: Expanding into high-growth regulated markets, reducing operational costs through efficiency improvements

Industry Trends & Business Environment

  • Global pharmaceutical market expected to reach USD 2,350 Billion by 2030
  • Strong generic drug demand across regulated and emerging markets
  • India's R&D cost base 87% lower than developed markets
  • 40% of global generics supplied by India
  • Indian pharma market projected to reach USD 130 Billion by 2030 from USD 55 Billion (CAGR 12.25%)
  • Chronic disease prevalence expanding therapy demand
  • Government incentives: PLI Scheme (₹15,000 Cr), tech-upgradation programs

Impact on Company: Benefiting from global demand surge, cost arbitrage advantages, and domestic consumption growth

Management Commentary & Growth Outlook

Strategic Outlook: "Q2FY27 is a strong validation of the strategic choices we made earlier. Our transition from an API manufacturer to a focused FDF manufacturer, and the scale-up of operations on that platform, is now clearly visible in our performance."

FY Guidance:

  • FY27 revenue growth expectation: more than 50%
  • Medium-term revenue CAGR: 20-25%
  • EBITDA margin expansion: 200-300 BPS
  • Scaling to ₹1,500+ Cr revenue by FY30

Growth Triggers:

  • CDMO partnership commercialized with ₹100-130 Cr incremental revenue expected in FY27
  • Greenfield expansion in UAE, Uzbekistan, West Africa
  • 300+ dossier filings by FY27
  • Domestic business growth at 15-20% CAGR

Risks and Opportunities: Focus on building compliance-led, differentiated FDF platform and sustaining profitable growth

ESG Updates

Not Specified

Digital Transformation

Not Specified